Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data.
Recursion?s rich, relatable database of more than a petabyte of biological images generated in-house on the company?s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.
Total Funding: $121M
Funding Stage: Series F
Business Stage: Growth
Market: B2B
Company Size: 101 to 250
Founded: 2013
Sep 2020
- AI Drug Discovery Startup Recursion Enters Unicorn Club with USD 239M Series D led by Bayer
Sep 2020
- Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases
Jul 2020
- Recursion Acquires Vium Bolstering Its Efforts to Industrialize Drug Discovery
Jul 2020
- Recursion Acquires Vium Bolstering Its Efforts to Industrialize Drug Discovery
Senior Machine Learning Scientist, Computer Vision
Salt Lake City, Utah
Machine Learning Scientist, Chemistry
Salt Lake City, Utah
Senior Software Engineer: Data Platform
Salt Lake City, Utah
Senior Software Engineer, Analysis Platform
Salt Lake City, Utah
Senior Software Engineer
Salt Lake City, Utah
